Cancer patients who smoke more likely to quit with frequent, sustained telephone counseling

NewsGuard 100/100 Score

Recently diagnosed cancer patients who smoke are significantly more likely to quit and remain tobacco-free if they receive frequent and sustained telephone counseling, according to a new study led by researchers at Massachusetts General Hospital (MGH). The study, published in JAMA, offers hope that these patients will respond better to treatment and enjoy improved quality of life while coping with cancer.

Studies suggest that between 10 percent and 30 percent of tobacco users who are diagnosed with cancer continue smoking. Moreover, half of those who stop relapse quickly. Cancer patients are not routinely referred to smoking-cessation programs, says psychologist Elyse R. Park, PhD, MPH, director of behavioral sciences at MGH's Tobacco Research and Treatment Center, and the lead author of the JAMA paper. Many clinicians may be reluctant to discuss the topic or may only recommend quitting to patients who have a smoking-related disease, such as lung cancer. However, explains Park, smoking can diminish the effectiveness of cancer treatment, as well as quality of life, for people with all forms of cancer.

"Cancer patients need help in order to achieve the best cancer treatment outcomes," says Park. Overall, fewer than 10 percent of smokers who attempt to quit succeed, according to the Centers for Disease Control and Prevention. Telephone counseling administered by certified tobacco treatment counselors has been shown to be an effective way to help smokers give up the habit, but most programs are relatively short term and focused on cancer prevention.

Park and her team at MGH joined forces with psychologist Jamie S. Ostroff, PhD, and her colleagues at Memorial Sloan Kettering Cancer Center in New York City to investigate whether a sustained, more intensive program would improve quit rates among cancer patients.

The study included 303 patients with various forms of cancer. Half of the participants received phone calls from counselors four times a week for a month; during these sessions, counselors used evidence-based behavioral strategies designed to motivate the patient to continue abstaining from tobacco and cope with the stress of a cancer diagnosis.

Patients also received advice about medications to aid smoking cessation, such as nicotine-replacement therapy. The intensive-treatment group received a similar schedule of telephone counseling, plus an additional four sessions every other week, for two months, and three monthly booster sessions. Patients in this group were also offered free smoking-cessation medications.

After six months, lab tests confirmed that 34.5 percent of the patients in the intensive-treatment program were abstaining from tobacco, compared to 21.5 percent of participants who received the shorter program with less frequent counseling.

We believe it was the ongoing, positive cessation support, in coordination with the oncology care these patients received, that led to the high success rate in the intensive-treatment group."

Elyse R. Park, PhD, MPH, director of behavioral sciences at MGH's Tobacco Research and Treatment Center

Park and her colleagues are now implementing this intensive tobacco treatment program at more than 40 community cancer centers around the United States. "This randomized trial demonstrated that tobacco treatment can and should be an integral part of comprehensive cancer care," says Park. "Cessation advice and support should start immediately, at the time of diagnosis, and it should be offered to all cancer patients, regardless of tumor type and stage of disease."

Source:
Journal reference:

Park, E.R., et al. (2020) Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer: A Randomized Clinical Trial. JAMA. doi.org/10.1001/jama.2020.14581.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer